Rutten-van Mölken MP - Search Results

1

Methodological issues of patient utility measurement. Experience from two clinical trials.

Rutten-van Mölken MP, Bakker CH, van Doorslaer EK, van der Linden S. Rutten-van Mölken MP, et al. Med Care. 1995 Sep;33(9):922-37. doi: 10.1097/00005650-199509000-00004. Med Care. 1995. PMID: 7666706 Clinical Trial.

2

Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of life.

van Schayck CP, Rutten-van Mölken MP, van Doorslaer EK, Folgering H, van Weel C. van Schayck CP, et al. Chest. 1992 Nov;102(5):1384-91. doi: 10.1378/chest.102.5.1384. Chest. 1992. PMID: 1424856 Clinical Trial.

3

Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life.

Rutten-van Mölken MP, Custers F, van Doorslaer EK, Jansen CC, Heurman L, Maesen FP, Smeets JJ, Bommer AM, Raaijmakers JA. Rutten-van Mölken MP, et al. Eur Respir J. 1995 Jun;8(6):888-98. Eur Respir J. 1995. PMID: 7589374 Free article. Clinical Trial.

4

Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.

Rutten-van Mölken MP, Van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FF. Rutten-van Mölken MP, et al. Am J Respir Crit Care Med. 1995 Apr;151(4):975-82. doi: 10.1164/ajrccm.151.4.7697275. Am J Respir Crit Care Med. 1995. PMID: 7697275 Clinical Trial.

5

Statistical analysis of cost outcomes in a randomized controlled clinical trial.

Rutten-van Mölken MP, van Doorslaer EK, van Vliet RC. Rutten-van Mölken MP, et al. Health Econ. 1994 Sep-Oct;3(5):333-45. doi: 10.1002/hec.4730030507. Health Econ. 1994. PMID: 7827649

6

Patient utilities in ankylosing spondylitis and the association with other outcome measures.

Bakker C, Rutten-van Mölken M, Hidding A, van Doorslaer E, Bennett K, van der Linden S. Bakker C, et al. J Rheumatol. 1994 Jul;21(7):1298-304. J Rheumatol. 1994. PMID: 7966073 Clinical Trial.

7

Health related utility measurement in rheumatology: an introduction.

Bakker CH, Rutten-van Mölken M, van Doorslaer E, Bennett K, van der Linden S. Bakker CH, et al. Patient Educ Couns. 1993 May;20(2-3):145-52. doi: 10.1016/0738-3991(93)90128-j. Patient Educ Couns. 1993. PMID: 8337191 Free article.

8

Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma.

Rutten-van Mölken MP, Van Doorslaer EK, Jansen MC, Van Essen-Zandvliet EE, Rutten FF. Rutten-van Mölken MP, et al. Pharmacoeconomics. 1993 Oct;4(4):257-70. doi: 10.2165/00019053-199304040-00004. Pharmacoeconomics. 1993. PMID: 10146915

9

Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method?

Goossens ME, Vlaeyen JW, Rutten-van Mölken MP, van der Linden SM. Goossens ME, et al. Pain. 1999 Mar;80(1-2):365-75. doi: 10.1016/s0304-3959(98)00232-2. Pain. 1999. PMID: 10204750 Clinical Trial.

10

Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma.

Rutten-van Mölken MP, van Doorslaer EK, Till MD. Rutten-van Mölken MP, et al. Pharmacoeconomics. 1998 Dec;14(6):671-84. doi: 10.2165/00019053-199814060-00007. Pharmacoeconomics. 1998. PMID: 10346418 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

220 results

Search Page

Filters